3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
6
Carcinoma, Hepatocellular
2
Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available
1
Neoplasms
1
Deafness, Autosomal Recessive 39
1
Colorectal Neoplasms
1
Adenocarcinoma
1
Interventions
pembrolizumab
133
Gemcitabine
101
Paclitaxel
100
Carboplatin
84
Nivolumab
66
Docetaxel
62
Bevacizumab
62
Cisplatin
57
Pemetrexed
50
Fluorouracil
49
Cyclophosphamide
41
Cetuximab
41
trametinib
38
venetoclax
37
Leucovorin
37
Irinotecan
37
Sorafenib
35
Capecitabine
35
Ipilimumab
33
Dexamethasone
32
atezolizumab
31
Erlotinib Hydrochloride
28
130-nm albumin-bound paclitaxel
28
Drug Therapy
27
Epoetin Alfa
26
Doxorubicin
25
Oxaliplatin
24
Albumin-Bound Paclitaxel
24
Prednisone
23
Rituximab
22
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neoplasms
×
tepotinib
×
Clear all
NCT02864992
2026-04-13
VISION
EMD Serono
Phase 2
Active not recruiting
337 enrolled
13 charts
2 FDA